Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lallemand Pharma International

Division of Lallemand Inc.
www.lallemandpharma.com

Latest From KeraVision Inc.

Cardiac Dimensions Inc.

Despite studies that show that patient in earlier stages of mitral regurgitation experience better rates of mortality and long term survival following valve repair surgeries, clinicians reserve the invasive procedures for the more seriously ill congestive heart failure patients.
Medical Device Platform Technologies

C&C Vision: Small Company, Big Vision

Presbyopia, the inability to focus close-up that come with aging, represents a blockbuster market opportunity since virtually everyone eventually suffers from the condition. The success of LASIK (laser surgery for vision correction) has created a demand on the part of patients and physicians for an alternative to glasses for the middle aged. C&C Vision hopes to be the first to offer a surgical treatment for presbyopia. Like others going after the market, however, C&C aims to validate its technology by addressing a medical need first: it is initially targeting cataracts. In doing so, however, it faces the risk of sidling up to, rather than directly attacking, the presbyopia market upon which it desires to be valued.
Medical Device Regulation

Transactions 1999: Dealmaking for the New Economy

The number of early-stage deals plummeted as large drug companies fought their way through mergers and other late-stage deals designed to boost near-term earnings. Drug companies also looked to mergers to build up sales forces and, by building bigger-selling products, to compensate for the lack of R&D productivity. Meanwhile, biotechs, with valuations at record levels, looked to find deals that would allow them to keep the upside of their products and move their share prices up.
BioPharmaceutical Medical Device

Refractec Inc.

Refractec hopes to offer a low-cost alternative to LASIK, a new, non-laser treatment for the underserved group of patients that suffers from farsightedness or hyperopia.
Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Lallemand Inc.
  • Senior Management
  • Contact Info
  • Lallemand Pharma International
    Phone: 91 980 4613
    Bahnhofstrasse 7
    Zug, 6301
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register